Cargando…
Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708475/ https://www.ncbi.nlm.nih.gov/pubmed/34946232 http://dx.doi.org/10.3390/medicina57121287 |
_version_ | 1784622694168264704 |
---|---|
author | Sowa-Staszczak, Anna Opalińska, Marta Kurzyńska, Anna Morawiec-Sławek, Karolina Gilis-Januszewska, Aleksandra Palen-Tytko, Joanna Olearska, Helena Hubalewska-Dydejczyk, Alicja |
author_facet | Sowa-Staszczak, Anna Opalińska, Marta Kurzyńska, Anna Morawiec-Sławek, Karolina Gilis-Januszewska, Aleksandra Palen-Tytko, Joanna Olearska, Helena Hubalewska-Dydejczyk, Alicja |
author_sort | Sowa-Staszczak, Anna |
collection | PubMed |
description | Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these SSAs are usually administered via injections repeated every 4 weeks. The purpose of the study was to compare the route of SSA administration (injection performed by professional medical staff and self-administration of the drug) with progression-free survival. Materials and methods: 88 patients in 2019 and 96 patients in 2020 with locally advanced or metastatic well-differentiated NETs were included in the study. All patients had a good expression of SSTR type 2 and had been treated for at least 3 months with a stable dose of long-acting somatostatin analogue every 4 weeks. All of them had received training on drug self-injections from professional NET nurses at the beginning of the COVID-19 epidemic. Results: The rate of NET progression in the study group in 2020 was higher than in 2019 29.1% vs. 18.1% (28 vs. 16 cases), p = 0.081. Conclusions: The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation. |
format | Online Article Text |
id | pubmed-8708475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87084752021-12-25 Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? Sowa-Staszczak, Anna Opalińska, Marta Kurzyńska, Anna Morawiec-Sławek, Karolina Gilis-Januszewska, Aleksandra Palen-Tytko, Joanna Olearska, Helena Hubalewska-Dydejczyk, Alicja Medicina (Kaunas) Article Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these SSAs are usually administered via injections repeated every 4 weeks. The purpose of the study was to compare the route of SSA administration (injection performed by professional medical staff and self-administration of the drug) with progression-free survival. Materials and methods: 88 patients in 2019 and 96 patients in 2020 with locally advanced or metastatic well-differentiated NETs were included in the study. All patients had a good expression of SSTR type 2 and had been treated for at least 3 months with a stable dose of long-acting somatostatin analogue every 4 weeks. All of them had received training on drug self-injections from professional NET nurses at the beginning of the COVID-19 epidemic. Results: The rate of NET progression in the study group in 2020 was higher than in 2019 29.1% vs. 18.1% (28 vs. 16 cases), p = 0.081. Conclusions: The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation. MDPI 2021-11-23 /pmc/articles/PMC8708475/ /pubmed/34946232 http://dx.doi.org/10.3390/medicina57121287 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sowa-Staszczak, Anna Opalińska, Marta Kurzyńska, Anna Morawiec-Sławek, Karolina Gilis-Januszewska, Aleksandra Palen-Tytko, Joanna Olearska, Helena Hubalewska-Dydejczyk, Alicja Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? |
title | Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? |
title_full | Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? |
title_fullStr | Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? |
title_full_unstemmed | Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? |
title_short | Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? |
title_sort | self-administration of long-acting somatostatin analogues in net patients—does it affect the clinical outcome? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708475/ https://www.ncbi.nlm.nih.gov/pubmed/34946232 http://dx.doi.org/10.3390/medicina57121287 |
work_keys_str_mv | AT sowastaszczakanna selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT opalinskamarta selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT kurzynskaanna selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT morawiecsławekkarolina selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT gilisjanuszewskaaleksandra selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT palentytkojoanna selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT olearskahelena selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome AT hubalewskadydejczykalicja selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome |